GSK and Pfizer Join Forces to Create New HIV Firm

By Taskin Ahmed

Pharma Deals Review: Vol 2009 Issue 4 (Table of Contents)

Published: 16 Apr-2009

DOI: 10.3833/pdr.v2009.i4.1096     ISSN: 1756-7874

Section: Joint Venture

Fulltext:

Abstract

GlaxoSmithKline and Pfizer have agreed to pool their resources in HIV to create a new specialist company that will hold 19% of the market for HIV treatments. The two companies said that it will be more sustainable and broader in scope than either company's individually. GSK will have an 85% stake in the joint venture and Pfizer will have 15%.

Copyright: © IQVIA 2018

PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details